Induced pluripotent stem cells (iPSCs) and their differentiated derivatives can potentially be
applied to cell-based therapy for human diseases. The properties of iPSCs are being …

Human embryonic stem cells (hESCs) can undergo unlimited self-renewal and differentiate
into all cell types in human body, and therefore hold great potential for cell therapy of …

Clinical success of adoptive cell therapy with chimeric antigen receptor (CAR) T cells for
treating hematological malignancies has revolutionized the field of cellular immunotherapy …

Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed
to the pluripotent state from which they can then be differentiated into any cell type of the …

Progress in adoptive T-cell therapy for cancer and infectious diseases, is hampered by the
lack of readily available, antigen-specific, human T lymphocytes. Pluripotent stem cells could …

Induced pluripotent stem cells (iPSCs) can self-renew indefinitely in culture and differentiate
into all specialized cell types including gametes. iPSCs do not exist naturally and are …

Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable …

Multilineage tissue-source mesenchymal stem cells (MSCs) possess strong
immunomodulatory properties and are excellent therapeutic agents, but require constant …

Induced pluripotent stem cell (iPSC)-derived effector cells offer distinct advantages for
immune therapy over existing patient-or donor-derived platforms, both in terms of scalable …

Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for
patient-specific cell-based organ repair strategies. However, their generation and …